| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Galectin Therapeutics Inc (GALT) has 14 insiders with recent SEC Form 4 filings, including 3 buys and 11 sells. GALT is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 10.33M | $22.99M | - | |
| 10% | 5.61M | $12.49M | - | |
| CFO | 100.0K | $222.5K | - | |
| CEO | 100.0K | $222.5K | - | |
| Other | 100.0K | $222.5K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 4, 2018 | Czirr James C | - | Sell | 50,000 | $5.12 | $256,080.93 | -0.8% | |
| Jun 1, 2018 | Shlevin Harold H.89 | Chief Operating Officer | Sale+OE | 119,200 | $5.06 | $602,920.00 | -52.5% | |
| May 31, 2018 | Callicutt Jack W62 | Chief Financial Officer | Sale+OE | 46,651 | $5.00 | $233,255.00 | -97.4% | |
| Apr 16, 2018 | Zucconi Theodore Daniel | Director | Sale+OE | 4,000 | $3.58 | $14,320.00 | -78.7% | |
| Apr 4, 2018 | Callicutt Jack W62 | Chief Financial Officer | Sale+OE | 3,349 | $5.00 | $16,745.00 | -72.7% | |
| Feb 1, 2018 | Freeman Kevin D56 | Director | Buy | 2,000 | $4.10 | $8,191.00 | +14.3% | |
| Feb 1, 2018 | Freeman Kevin D56 | Director | Buy | 2,000 | $4.10 | $8,191.00 | +14.3% | |
| Jan 26, 2018 | Czirr James C | Director | Sell | 244,444 | $5.43 | $1,328,289.80 | -3.7% | |
| Jan 26, 2018 | 10x Fund, L.P.85 | 10% Owner | Sell | 244,444 | $5.43 | $1,328,289.80 | -3.7% | |
| Dec 8, 2017 | Rubin Marc | Director | Buy | 7,000 | $1.85 | $12,971.70 | +14.4% |